MyFinsight
Home
Blog
About
Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics, Inc. (LRMR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$85,376K
Free Cash flow
-$44,160K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Stock-based compensation expense
Other income, net
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Accrued expenses
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Operating expenses
34,351
31,117
172,497
-
Other income, net
1,569
1,504
6,824
-
Net loss
-32,782
-29,613
-110,210
-
Stock-based compensation expense
2,149
1,979
3,342
-
Lease expense
-12
-85
-148
-
Depreciation expense
62
64
175
-
Amortization of premium on marketable securities
-345
-80
-482
-
Prepaid expenses and other current assets
-187
-578
-1,862
-
Accounts payable
-557
2,925
1,070
-
Accrued expenses
-12,756
-20,401
37,073
-
Other assets
-24
-19
-38
-
Net cash used in operating activities
-44,030
-44,614
-67,280
-
Purchases of property and equipment
130
-
23
-
Purchases of marketable securities
63,281
-
3,458
-
Maturities of marketable securities
22,500
29,000
184,000
-
Net cash provided by (used in) investing activities
-40,911
29,000
67,019
-
Proceeds from issuance of equity securities
-435
108,101
-
-
Proceeds from issuance of common stock, net of issuance costs
-
-
65,086
-
Proceeds from exercise of stock options
0
14
-
-
Net cash provided by financing activities
-435
108,115
65,086
-
Net increase in cash, cash equivalents and restricted cash
-85,376
92,501
-4,728
69,553
Cash, cash equivalents and restricted cash at beginning of period
178,519
86,018
90,746
33,824
Cash, cash equivalents and restricted cash at end of period
93,143
178,519
86,018
90,746
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase in
cash, cash...
-$85,376K
(-575.92%↓ Y/Y)
Stock-based compensation
expense
$2,149K
(-41.32%↓ Y/Y)
Prepaid expenses and
other current assets
-$187K
(96.12%↑ Y/Y)
Depreciation expense
$62K
(-64.57%↓ Y/Y)
Other assets
-$24K
(31.43%↑ Y/Y)
Maturities of marketable
securities
$22,500K
(-80.18%↓ Y/Y)
Net cash used in
operating activities
-$44,030K
(4.12%↑ Y/Y)
Net cash provided by
(used in) investing...
-$40,911K
(-222.89%↓ Y/Y)
Net cash provided by
financing activities
-$435K
Canceled cashflow
$2,422K
Canceled cashflow
$22,500K
Other income, net
$1,569K
Net loss
-$32,782K
(40.89%↑ Y/Y)
Accrued expenses
-$12,756K
(-2763.05%↓ Y/Y)
Purchases of marketable
securities
$63,281K
(-21.04%↓ Y/Y)
Proceeds from issuance of
equity securities
-$435K
Canceled cashflow
$1,569K
Accounts payable
-$557K
(-132.35%↓ Y/Y)
Amortization of premium on
marketable securities
-$345K
(71.63%↑ Y/Y)
Lease expense
-$12K
(90.98%↑ Y/Y)
Purchases of property and
equipment
$130K
(91.18%↑ Y/Y)
Operating expenses
$34,351K
Buy us a coffee